Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB-0,25
PKN96,4696,62,33
Msft-1,16
Nokia4,7464,792,40
IBM-0,76
Daimler AG47,4247,435-0,17
PFE0,49
21.09.2019 2:00:00
Indexy online
AD Index online
select
AD Index online
 

  • 20.09.2019
Amgen Inc (AMGN.O, NASDAQ Cons)
Závěr k 20.9.2019 Změna (%) Změna (USD) Objem obchodů (ks)
196,94 0,66 1,29 6 907 346
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 22.09.2019
Popis společnosti
Obecné informace
Název společnostiAmgen, Inc.
TickerAMGN
Kmenové akcie:Ordinary Shares
RICAMGN.O
ISINUS0311621009
Poslední známé roční výsledky31.12.2018
Poslední známé čtvrtletní výsledky30.06.2019
Počet zaměstnanců k 31.12.2018 21 500
Akcie v oběhu k 24.07.2019 599 701 222
Počet akcionářů k 31.12.2018 5 760
MěnaUSD
Konstituent indexůS&P 500
Kontaktní informace
Ulice1 Amgen Center Dr
MěstoTHOUSAND OAKS
PSČ91320-1730
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon18 054 471 000
Fax18054471010

Business Summary: Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Financial Summary: BRIEF: For the six months ended 30 June 2019, Amgen, Inc. revenues decreased 2% to $11.43B. Net income decreased 9% to $4.17B. Revenues reflect Product Sales decrease of 1% to $10.86B, Other Reveneus decrease of 4% to $568M. Net income also reflects Research and development increase of 11% to $1.8B (expense), Other decrease of 73% to $6M (income). Dividend per share increased from $2.64 to $2.90.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Pharmaceuticals - NEC
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSPharmaceutical Preparation Manufacturing
SICBiological Prod's Not Diagnostic
SICCommercial Physical Research
SICBiological Prod's Not Diagnostic
SICPharmaceutical Preparations



  • Poslední aktualizace: 22.09.2019
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, President, Chief Executive OfficerRobert Bradway5601.01.201310.04.2007
Executive Vice President, Chief Financial OfficerDavid Meline6221.07.201421.07.2014
Executive Vice President of Global Commercial OperationsMurdo Gordon5203.09.201803.09.2018
Executive Vice President - Research and DevelopmentDavid Reese5626.07.201826.07.2018
Executive Vice President, OperationsEsteban Santos51
Senior Vice President, Chief Compliance OfficerCynthia Patton5722.10.201222.10.2012
Senior Vice President, General Counsel, SecretaryJonathan Graham58
Senior Vice President - Human ResourcesLori Johnston5402.11.2016
Senior Vice President - Business DevelopmentDavid Piacquad62